KR20230040993A - 헤테로아릴-바이페닐 아미드 유도체를 사용한 암 치료 방법 - Google Patents

헤테로아릴-바이페닐 아미드 유도체를 사용한 암 치료 방법 Download PDF

Info

Publication number
KR20230040993A
KR20230040993A KR1020237001820A KR20237001820A KR20230040993A KR 20230040993 A KR20230040993 A KR 20230040993A KR 1020237001820 A KR1020237001820 A KR 1020237001820A KR 20237001820 A KR20237001820 A KR 20237001820A KR 20230040993 A KR20230040993 A KR 20230040993A
Authority
KR
South Korea
Prior art keywords
group
cancer
formula
agents
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237001820A
Other languages
English (en)
Korean (ko)
Inventor
쉬지 리
마르타 빌랄타-콜로머
이빈 젱
펭리 장
Original Assignee
케모센트릭스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 케모센트릭스, 인크. filed Critical 케모센트릭스, 인크.
Publication of KR20230040993A publication Critical patent/KR20230040993A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020237001820A 2020-06-23 2021-06-22 헤테로아릴-바이페닐 아미드 유도체를 사용한 암 치료 방법 Pending KR20230040993A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063042807P 2020-06-23 2020-06-23
US63/042,807 2020-06-23
PCT/US2021/038339 WO2021262627A1 (en) 2020-06-23 2021-06-22 Methods of treating cancer using heteroaryl-biphenyl amide derivatives

Publications (1)

Publication Number Publication Date
KR20230040993A true KR20230040993A (ko) 2023-03-23

Family

ID=79022859

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237001820A Pending KR20230040993A (ko) 2020-06-23 2021-06-22 헤테로아릴-바이페닐 아미드 유도체를 사용한 암 치료 방법

Country Status (14)

Country Link
US (3) US20210393759A1 (cg-RX-API-DMAC7.html)
EP (1) EP4167991A4 (cg-RX-API-DMAC7.html)
JP (1) JP7804596B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230040993A (cg-RX-API-DMAC7.html)
CN (1) CN116472045B (cg-RX-API-DMAC7.html)
AU (1) AU2021297216B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022026397A2 (cg-RX-API-DMAC7.html)
CA (1) CA3187605A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022003716A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023000703A2 (cg-RX-API-DMAC7.html)
IL (1) IL299206A (cg-RX-API-DMAC7.html)
MX (1) MX2022016554A (cg-RX-API-DMAC7.html)
TW (1) TW202216694A (cg-RX-API-DMAC7.html)
WO (1) WO2021262627A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102670486B1 (ko) 2017-08-08 2024-05-28 케모센트릭스, 인크. 마크로사이클릭 면역조절제
WO2019165043A2 (en) 2018-02-22 2019-08-29 Chemocentryx, Inc. Indane-amines as pd-l1 antagonists
BR112021022659A2 (pt) 2019-05-15 2022-03-29 Chemocentryx Inc Compostos triarílicos para o tratamento de doenças pd-l1
KR102890201B1 (ko) 2019-07-10 2025-11-24 케모센트릭스, 인크. Pd-l1 억제제로서의 인단
ES3068390T3 (en) * 2019-10-16 2026-05-29 Chemocentryx Inc Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases
AU2020368392B2 (en) 2019-10-16 2026-01-08 Chemocentryx, Inc. Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8673919B2 (en) * 2009-03-27 2014-03-18 Ardea Biosciences, Inc. Dihydropyridin sulfonamides and dihydropyridin sulfamides as MEK inhibitors
EA023521B1 (ru) * 2011-11-14 2016-06-30 Сефалон, Инк. ПРОИЗВОДНЫЕ УРАЦИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ AXL И c-MET КИНАЗЫ
EP2788000B1 (en) * 2011-12-06 2018-05-30 Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors
US10308644B2 (en) * 2016-12-22 2019-06-04 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018119221A1 (en) * 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
CN106674136B (zh) * 2016-12-23 2019-07-02 中国医科大学 嘧啶类抗肿瘤化合物及其制备方法
US10919852B2 (en) * 2017-07-28 2021-02-16 Chemocentryx, Inc. Immunomodulator compounds
EP3735410A4 (en) * 2017-10-19 2021-11-03 Tempest Therapeutics, Inc. PICOLINAMIDE COMPOUNDS
WO2019160882A1 (en) * 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2019165043A2 (en) * 2018-02-22 2019-08-29 Chemocentryx, Inc. Indane-amines as pd-l1 antagonists
BR112021022659A2 (pt) * 2019-05-15 2022-03-29 Chemocentryx Inc Compostos triarílicos para o tratamento de doenças pd-l1
ES3068390T3 (en) * 2019-10-16 2026-05-29 Chemocentryx Inc Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases

Also Published As

Publication number Publication date
EP4167991A1 (en) 2023-04-26
US20240115682A1 (en) 2024-04-11
AU2021297216B2 (en) 2025-10-16
CN116472045B (zh) 2025-05-13
EP4167991A4 (en) 2024-07-24
TW202216694A (zh) 2022-05-01
WO2021262627A1 (en) 2021-12-30
CA3187605A1 (en) 2021-12-30
IL299206A (en) 2023-02-01
MX2022016554A (es) 2023-04-10
CL2022003716A1 (es) 2023-06-30
CO2023000703A2 (es) 2023-01-26
BR112022026397A2 (pt) 2023-03-14
US20250090646A1 (en) 2025-03-20
JP7804596B2 (ja) 2026-01-22
AU2021297216A1 (en) 2023-02-02
JP2023531970A (ja) 2023-07-26
CN116472045A (zh) 2023-07-21
US20210393759A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
US12533354B2 (en) Triaryl compounds for treatment of PD-L1 diseases
US11691985B2 (en) Macrocyclic immunomodulators
AU2021297216B2 (en) Methods of treating cancer using heteroaryl-biphenyl amide derivatives
US11485708B2 (en) Compounds for treatment of PD-L1 diseases
KR102401963B1 (ko) 면역조절제 화합물
ES2816060T3 (es) Aza-aril 1H-pirazol-1-il-bencenosulfonamidas como antagonistas de CCR(9)
JP7747614B2 (ja) Pd-l1阻害剤としてのインダン
TW201805279A (zh) 嘧啶酪氨酸激酶抑制劑
KR20220084119A (ko) Pd-l1 질환의 치료를 위한 헤테로아릴-바이페닐 아미드
JP2011525192A (ja) トリアゾロピリジンjak阻害剤化合物と方法
EA049712B1 (ru) Способы лечения рака с использованием производных гетероарилбифениламида
CA3152329C (en) Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases
RU2838028C2 (ru) Соединения для лечения pd-l1 заболеваний

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902